MAP7D1

Across TCGA pan-cancer cohorts, MAP7D1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MAP7D1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MAP7D1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP7D1 is over-expressed in tumor, although a few such as BLCA and BRCA show the opposite, repressed pattern.

HNSC, LIHC, and KIRC are the cancer types where MAP7D1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP7D1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.922	<.001	10	view →
LIHC	Female	II,III,IV	+1.509	<.001	9	view →
KIRC	Male	IV	+0.745	<.001	9	view →
THCA	Male	III,IV	+0.700	<.001	7	view →
BLCA	All	III,IV	−0.681	.010	6	view →
BRCA	All	II,III,IV	−0.544	<.001	6	view →
KICH	All	All	−0.799	<.001	4	view →
KIRP	All	All	+0.479	.003	4	view →
CHOL	Male	All	+2.841	<.001	3	view →
LUAD	All	All	−0.454	<.001	3	view →
READ	Female	All	−1.099	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MAP7D1–HNSC

Open the HNSC breakdown →